3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
36
Cholangiocarcinoma
11
Carcinoma, Renal Cell
10
Stomach Neoplasms
5
Liver Neoplasms
5
Neoplasms
4
Endometrial Neoplasms
4
Biliary Tract Neoplasms
4
Uterine Cervical Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Vulvar Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Recurrence
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Liver Diseases
2
Kidney Neoplasms
2
Cirrhosis, Familial, with Pulmonary Hypertension
2
Breast Neoplasms
2
Advanced Solid Tumor
2
von Hippel-Lindau Disease
1
Urogenital Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Solid Tumor, Adult
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Penile Neoplasms
1
Interventions
belzutifan
3
palbociclib
1
lenvatinib
1
gallium Ga 68 dotatate
1
cabozantinib
1
Propranolol
1
Nivolumab
1
Everolimus
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
von Hippel-Lindau Disease
×
lenvatinib
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled